Last reviewed · How we verify
Additive solution
At a glance
| Generic name | Additive solution |
|---|---|
| Sponsor | Etablissement Français du Sang |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Xylitol Use for Decolonization of C. Difficile in Patients With IBD (PHASE1)
- Innovative Technologies for Salvage Procedures of Failed Treatments of Osteoarthritis: Biomimetics Solutions (CustomPN)
- Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks (PHASE1, PHASE2)
- The Antiplaque and Antigingivitis Effect of Pure Green Tea Mouth Wash Compared to Placebo and Essential Oils Mouth Washes (NA)
- Delayed Cold-Stored Platelets -PLTS-1 (PHASE2)
- Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair (NA)
- Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (PHASE3)
- Ketamine Augmentation of ECT in Treatment-Resistant Depression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Additive solution CI brief — competitive landscape report
- Additive solution updates RSS · CI watch RSS
- Etablissement Français du Sang portfolio CI